Long-term results of the Italian association of pediatric hematology and oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia

V. Conter, M. Aricò, G. Basso, A. Biondi, E. Barisone, C. Messina, R. Parasole, G. De Rossi, F. Locatelli, A. Pession, N. Santoro, C. Micalizzi, M. Citterio, C. Rizzari, D. Silvestri, R. Rondelli, L. Lo Nigro, O. Ziino, A. M. Testi, G. MaseraM. G. Valsecchi

Research output: Contribution to journalArticle

Abstract

We analyzed the long-term outcome of 4865 patients treated in Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia (ALL) of the Italian Association of Pediatric Hematology and Oncology (AIEOP). Treatment was characterized by progressive intensification of systemic therapy and reduction of cranial radiotherapy. A progressive improvement of results with reduction of isolated central nervous system relapse rate was obtained. Ten-year event-free survival increased from 53% in Study 82 to 72% in Study 95, whereas survival improved from 64 to 82%. Since 1991, all patients were treated according to Berlin-Frankfurt-Muenster (BFM) ALL treatment strategy. In Study 91, reduced treatment intensity (25%) yielded inferior results, but intensification of maintenance with high-dose (HD)-L-asparaginase (randomized) allowed to compensate for this disadvantage; in high-risk patients (HR, 15%), substitution of intensive polychemotherapy blocks for conventional BFM backbone failed to improve results. A marked improvement of results was obtained in HR patients when conventional BFM therapy was intensified with three polychemotherapy blocks and double delayed intensification (Study 95). The introduction of minimal residual disease monitoring and evaluation of common randomized questions by AIEOP and BFM groups in the protocol AIEOP-BFM-ALL 2000 are expected to further ameliorate treatment of children with ALL.

Original languageEnglish
Pages (from-to)255-264
Number of pages10
JournalLeukemia
Volume24
Issue number2
DOIs
Publication statusPublished - Feb 2010

Keywords

  • Acute lymphoblastic leukemia
  • Childhood
  • Long-term results

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Fingerprint Dive into the research topics of 'Long-term results of the Italian association of pediatric hematology and oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia'. Together they form a unique fingerprint.

  • Cite this

    Conter, V., Aricò, M., Basso, G., Biondi, A., Barisone, E., Messina, C., Parasole, R., De Rossi, G., Locatelli, F., Pession, A., Santoro, N., Micalizzi, C., Citterio, M., Rizzari, C., Silvestri, D., Rondelli, R., Nigro, L. L., Ziino, O., Testi, A. M., ... Valsecchi, M. G. (2010). Long-term results of the Italian association of pediatric hematology and oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia. Leukemia, 24(2), 255-264. https://doi.org/10.1038/leu.2009.250